Different Genetic Features Associated With Hepatic Carcinogenesis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01247506
First received: November 22, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted
  Purpose

The purpose of this study is to identify different genetic features in hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of HCC.


Condition
Hepatocellular Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Identification of Survival-related microRNAs in Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples With DNA

HCC tissues and paired nontumor tissues


Estimated Enrollment: 160
Study Start Date: February 2010
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
tumor tissues of HCC patients
2
paired nontumor tissues of HCC patients

Detailed Description:

Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in Taiwan. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are current best curative options to treat HCC. However, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively.

MicroRNAs, small non-coding RNA, act as endogenous RNA interference by post-transcription regulation. Recent studies suggest that microRNAs may act as tumor suppressors or oncogenes and altered microRNA expression levels may play an important role in the cancer initiation and progression. Several studies, including ourselves, have shown that specific microRNAs are aberrantly expressed in malignant HCC tissues compared to normal counterpart. Although many microRNA profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. The main point of this study is to develop a predictive signature for postsurgical survival in HCC patients.

  Eligibility

Ages Eligible for Study:   45 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

A total of 160 patients with histologically proven HCC were collected by Dr. Po-Huang Lee's Lab (The Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)

Criteria

Inclusion Criteria:

  • clinical diagnosis of hepatocellular carcinoma

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01247506

Contacts
Contact: Tzu-Min Hung, PhD 886-2-23123456 ext 65956 mean6722@ms65.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Principal Investigator: Cheng-Maw HO         
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Investigators
Study Chair: Po-Huang Lee, PhD National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Po-Huang Lee, Proferrsor, Department of sugery, National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01247506     History of Changes
Other Study ID Numbers: 200912020R
Study First Received: November 22, 2010
Last Updated: November 22, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
microRNA

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on April 17, 2014